DexCom, Inc.
83.88USD
-0.6500 (-0.77%)
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 2.9B | 3.6B | 4.0B | 4.7B | 5.2B | 5.8B |
| Q1 | 628.8M | 741.5M | 921.0M | 1.0B | 1.2B | — |
| Q2 | 696.2M | 871.3M | 1.0B | 1.2B | 1.3B | — |
| Q3 | 769.6M | 975.0M | 994.2M | 1.2B | 1.3B | — |
| Q4 | 815.2M* | 1.0B* | 1.1B* | 1.3B* | 1.4B | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | .820 | 1.30 | 1.42 | 2.09 | 2.66 | 3.12 |
| Q1 | .230 | .120 | .360 | .270 | .510 | — |
| Q2 | .120 | .280 | .350 | .450 | .640 | — |
| Q3 | .240 | .290 | .340 | .700 | .671 | — |
| Q4 | .215* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| .602* |
| .368* |
| .659* |
| .734 |
| — |